Evaluation of safety of two inactivated COVID-19 vaccines in a large-scale emergency use
10.3760/cma.j.cn112338-20210325-00249
- VernacularTitle:新型冠状病毒灭活疫苗（Vero细胞）大规模紧急使用安全性评价
- Author:
Zhongnan YANG
1
;
Yunya ZHAO
;
Lu LI
;
Huidi GAO
;
Qi CAI
;
Xiaoxia SUN
;
Fusheng ZHANG
;
Jinfeng SU
;
Yinan ZHANG
;
Xiang SHU
;
Xuewei WANG
;
Yunkai YANG
;
Yuntao ZHANG
;
Song ZHOU
;
Xiaoming YANG
Author Information
1. 中国生物技术股份有限公司，北京 100024
- Keywords:
Inactivated COVID-19 vaccine;
Emergency use;
Safety
- From:
Chinese Journal of Epidemiology
2021;42(6):977-982
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the safety of two inactivated COVID-19 vaccines in a large-scale emergency use.Methods:Based on the "Vaccination Information Collection System", the incidence data of adverse reactions in the population vaccinated with the inactivated COVID-19 vaccines developed by Beijing Institute of Biological Products Co., Ltd and Wuhan Institute of Biological Products Co., Ltd, respectively, in emergency use were collected, and the relevant information were analyzed with descriptive epidemiological and statistical methods.Results:By December 1, 2020, the vaccination information of 519 543 individuals had been collected. The overall incidence rate of adverse reactions was 1.06%, the incidence rate of systemic adverse reactions was 0.69% and the incidence rate of local adverse reactions was 0.37%. The main systemic adverse reactions included fatigue, headache, fever, cough and loss of appetite with the incidence rates of 0.21%, 0.14%, 0.06%, 0.05% and 0.05%, respectively; the main local adverse reactions were injection site pain and injection site swelling with the incidence rates of 0.24% and 0.05%, respectively.Conclusion:The two inactivated COVID-19 vaccines by Beijing Institute of Biological Products Co., Ltd and Wuhan Institute of Biological Products Co., Ltd showed that in the large-scale emergency use, the incidence rate of general reactions was low and no serious adverse reactions were observed after the vaccinations, demonstrating that the vaccines have good safety.
